Pfizer's vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease
Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision
Enflosina is a long-acting monoclonal antibody that provides direct protection for up to 5 months
Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
Zydus will carry out early-stage development, animal immunogenicity studies and regulatory preclinical toxicology studies for this combination vaccine
Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y)
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
Company receives acceptability, in principle, for ZyVac TCV making it eligible for purchase by United Nations procurement agencies
India has been declared ‘functional’ against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI
Subscribe To Our Newsletter & Stay Updated
